Saroj Pharma has a diverse product range, including pharmaceuticals, pharma API, and pharma intermediates. They supply various products, such as Liquid Bromine, which is an Agro Intermediate, and Ethyl Acetate, which is used as an API solvent for agro intermediates.
Additionally, the company offers medications for both human and veterinary use, some of which serve as API solvents.
The company's reach extends across different regions, with a notable presence in both Indian and international markets. They have successfully exported their products to countries such as Pakistan, Egypt, Russia, Jordan, Hong Kong, and Singapore.
The company maintains a broad spectrum of brands within the pharmaceutical industry, covering various therapeutic areas. They also offer specialty and performance-enhancing products in the chemical industry.
Saroj Pharma relies heavily on its top customers. Its top 10 customers generated 83.51%, 68.92%, and 74.53% of operating revenue as of March 31 in 2023, 2022, and 2021, respectively. Losing major customers could severely impact the company's business.
The company's domestic sales are closely tied to the top 5 states in India. These states, including Andhra Pradesh, Gujarat, Maharashtra, Telangana, and Tamil Nadu, contributed nearly 89.67%, 77.29%, and 82.65% of its total revenue as of March 31 in 2023, 2022, and 2021, respectively.
The company's reliance on a limited number of suppliers poses another risk. The top 10 suppliers account for 62.86%, 68.15%, and 73.58% of their total purchases for the years ending on March 31 in 2023, 2022, and 2021, respectively.
The company handles hazardous materials and accidents involving these substances could result in liability for damages and legal proceedings.
The company has experienced negative cash flow in recent years.
The company relies on third-party transportation providers to deliver goods to and from suppliers and clients. Any failure by these service providers to meet their obligations could significantly impact the company's business.